These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 23221987)
21. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897 [TBL] [Abstract][Full Text] [Related]
22. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management. Tesařová P; Tesař V Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524 [TBL] [Abstract][Full Text] [Related]
23. Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole. Faehling M; Kroll J; Föhr KJ; Fellbrich G; Mayr U; Trischler G; Waltenberger J FASEB J; 2002 Nov; 16(13):1805-7. PubMed ID: 12354692 [TBL] [Abstract][Full Text] [Related]
24. [Therapeutic strategies using VEGF inhibitors in colorectal cancer]. Boige V; Malka D; Ducreux M Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667 [TBL] [Abstract][Full Text] [Related]
25. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood JM Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380 [TBL] [Abstract][Full Text] [Related]
28. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. Kim CK; Choi YK; Lee H; Ha KS; Won MH; Kwon YG; Kim YM Mol Pharmacol; 2010 Jul; 78(1):142-50. PubMed ID: 20406854 [TBL] [Abstract][Full Text] [Related]
29. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Pradeep CR; Sunila ES; Kuttan G Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508 [TBL] [Abstract][Full Text] [Related]
30. The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. Saleh L; Verdonk K; Visser W; van den Meiracker AH; Danser AH Ther Adv Cardiovasc Dis; 2016 Oct; 10(5):282-93. PubMed ID: 26755746 [TBL] [Abstract][Full Text] [Related]
31. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
32. VEGF as a therapeutic target in cancer. Ferrara N Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831 [TBL] [Abstract][Full Text] [Related]
33. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Kiselyov A; Balakin KV; Tkachenko SE Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856 [TBL] [Abstract][Full Text] [Related]
34. Nitric oxide and adverse events of vascular endothelial growth factor inhibitors. Thachil J Curr Med Res Opin; 2011 Aug; 27(8):1503-7. PubMed ID: 21651424 [TBL] [Abstract][Full Text] [Related]
35. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638 [TBL] [Abstract][Full Text] [Related]
38. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo. Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909 [TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592 [TBL] [Abstract][Full Text] [Related]
40. Endostatin down-regulates soluble guanylate cyclase (sGC) in endothelial cells in vivo: influence of endostatin on vascular endothelial growth factor (VEGF) signaling. Schmidt A; Wenzel D; Thorey I; Werner S; Fleischmann BK; Bloch W Endothelium; 2005; 12(5-6):251-7. PubMed ID: 16410224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]